Details

Autor(en) / Beteiligte

• Hyeon, Do Young
• Nam, Dowoon
• Han, Youngmin
• Kim, Duk Ki
• Kim, Gibeom
• Kim, Daeun
• Bae, Jingi
• Back, Seunghoon
• Mun, Dong-Gi
• Madar, Inamul Hasan
• Lee, Hangyeore
• Kim, Su-Jin
• Kim, Hokeun
• Hyun, Sangyeop
• Kim, Chang Rok
• Choi, Seon Ah
• Kim, Yong Ryoul
• Jeong, Juhee
• Jeon, Suwan
• Choo, Yeon Woong
• Lee, Kyung Bun
• Kwon, Wooil
• Choi, Seunghyuk
• Goo, Taewan
• Park, Taesung
• Suh, Young-Ah
• Kim, Hongbeom
• Ku, Ja-Lok
• Kim, Min-Sik
• Paek, Eunok
• Park, Daechan
• Jung, Keehoon
• Baek, Sung Hee
• Jang, Jin-Young
• Hwang, Daehee
• Lee, Sang-Won

Titel

Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes

Ist Teil von

• Nature cancer, 2023-02, Vol.4 (2), p.290

Ort / Verlag

England

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• We report a proteogenomic analysis of pancreatic ductal adenocarcinoma (PDAC). Mutation-phosphorylation correlations identified signaling pathways associated with somatic mutations in significantly mutated genes. Messenger RNA-protein abundance correlations revealed potential prognostic biomarkers correlated with patient survival. Integrated clustering of mRNA, protein and phosphorylation data identified six PDAC subtypes. Cellular pathways represented by mRNA and protein signatures, defining the subtypes and compositions of cell types in the subtypes, characterized them as classical progenitor (TS1), squamous (TS2-4), immunogenic progenitor (IS1) and exocrine-like (IS2) subtypes. Compared with the mRNA data, protein and phosphorylation data further classified the squamous subtypes into activated stroma-enriched (TS2), invasive (TS3) and invasive-proliferative (TS4) squamous subtypes. Orthotopic mouse PDAC models revealed a higher number of pro-tumorigenic immune cells in TS4, inhibiting T cell proliferation. Our proteogenomic analysis provides significantly mutated genes/biomarkers, cellular pathways and cell types as potential therapeutic targets to improve stratification of patients with PDAC.